Search for Clinical Trial Results

Sponsored By

Cylindroma - 25 Studies Found

Status Study
Recruiting Study Name: Pembrolizumab With or Without Radiation in Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma
Condition: Adenoid Cystic Carcinoma
Date: 2017-03-13
Interventions:
  • Radiation: Radiation Standard

Completed Study Name: Study of RAD001 in Adenoid Cystic Carcinoma
Condition: Adenoid Cystic Carcinoma
Date: 2010-05-31
Interventions: Drug: RAD001 RAD001 10 mg po daily medication
Not yet recruiting Study Name: Chidamide for Advanced Cephalic and Cervical Adenocystic Carcinoma: Evaluation of Efficiency and Safety
Condition: Adenocystic Carcinoma
Date: 2016-08-25
Interventions: Drug: Chidamide Other Name: epidaza
Completed Study Name: Phase II Trial of Doxorubicin and Bortezomib in Patients With Incurable Adenoid Cystic Carcinoma of the Head and Neck
Condition: Adenoid Cystic Carcinoma
Date: 2007-12-19
Interventions: Drug: doxorubicin and bortezomib Patients will be treated with bortezomib 1.3 mg/m2, intravenously on da
Recruiting Study Name: Adenoid Cystic Carcinoma, Erbitux, and Particle Therapy
Condition: Adenoid Cystic Carcinoma
Date: 2010-08-30
Interventions: Drug: Cetuximab cetuximab initial dose (7 days prior to RT treatment start): 400 mg/m² body surface
Completed Study Name: Dovitinib in Adenoid Cystic Carcinoma
Condition: Adenoid Cystic Carcinoma
Date: 2011-08-09
Interventions: Drug: TKI258 (Dovitinib): TKI258 (Dovitinib): 500 mg daily po medication with 5 days on/2 days off sched
Recruiting Study Name: Testing Lenvatinib in Patients With Adenoid Cystic Carcinoma
Condition: Adenoid Cystic Carcinoma
Date: 2016-05-19
Interventions: Drug: Lenvatinib
Completed Study Name: Study of Dovitinib (TKI258) in Adenoid Cystic Carcinoma
Condition: Adenoid Cystic Carcinoma
Date: 2012-01-17
Interventions: Drug: Dovitinib (TKI258) 500 mg orally on a 5-days on/2-days off schedule each week of a 4-week (28-day)
Completed Study Name: Compassionate Use of Brontictuzumab for Adenoid Cystic Carcinoma (ACC)
Condition: Adenoid Cystic Carcinoma
Date: 2016-01-22
Interventions: Drug: Brontictuzumab 1.5 mg/Kg intravenously every three weeks.
Active, not recruiting Study Name: Regorafenib in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma
Condition: Adenoid Cystic Carcinoma
Date: 2014-03-24
Interventions: Drug: Regorafenib All eligible patients will receive a starting regorafenib dose of 120 mg daily taken o
Next >>>